Regenxbio reports Q3 EPS ($1.20), consensus ($1.30)

Reports Q3 revenue $29.7M, consensus $24.41M. “The positive data and significant clinical milestones achieved across each of our late-stage programs underscore the meaningful progress we’re making towards delivering potentially transformative gene therapies,” said Curran Simpson, President and Chief Executive Officer of REGENXBIO (RGNX). “Our strong momentum is driven by our differentiated, in-house end-to-end capabilities, including commercial-ready manufacturing with capacity to seize blockbuster opportunities, and a deep commitment to improve the lives of patients with Duchenne, Hunter syndrome, wet AMD and diabetic retinopathy. With the rapid advancement of our programs and leading technology platform, we are well-positioned to become a commercial company early next year.”